Sherbrooke Park Advisers’s Fulcrum Therapeutics FULC Stock Holding History

Sherbrooke Park Advisers’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,201	Closed	-$187K	–	594
2025 Q2	$187K	Sell	27,201 -28,141	-51%	-$151K	0.08%	403
2025 Q1	$159K	Buy	55,342 +10,185	+23%	+$37.4K	0.07%	456
2024 Q4	$212K	Sell	45,157 -182,068	-80%	-$672K	0.07%	560
2024 Q3	$811K	Buy	+227,225	New	+$1.69M	0.19%	131
2024 Q1	–	Sell	-11,684	Closed	-$78.9K	–	892
2023 Q4	$78.9K	Buy	+11,684	New	+$51.8K	0.04%	417

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sherbrooke Park Advisers's FULC Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Fulcrum Therapeutics (FULC) in Q3 2025, closing a stake of 27,201 shares — an estimated $187K sold.

Sherbrooke Park Advisers first reported a position in FULC in Q4 2023 and held it in 5 quarters. The position peaked at $811K in Q3 2024. 129 funds tracked by Wall St. Rank hold FULC as of Q3 2025.

Sherbrooke Park Advisers reported no remaining Fulcrum Therapeutics position as of Q3 2025 after selling out during the quarter.
Sherbrooke Park Advisers sold 27,201 Fulcrum Therapeutics shares in Q3 2025, an estimated $187K.
Sherbrooke Park Advisers first reported a position in Fulcrum Therapeutics in Q4 2023 and held it in 5 quarters.
Sherbrooke Park Advisers's Fulcrum Therapeutics position peaked at $811K in Q3 2024.
129 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.